CEO of Antibody Maker Covid Vir Biotech Says Their Treatment ‘Holds Up’ To All Variants – .

0
11
CEO of Antibody Maker Covid Vir Biotech Says Their Treatment ‘Holds Up’ To All Variants – .


A Covid monoclonal antibody treatment from Vir Biotechnology and GlaxoSmithKline “resists well” to all variants of the virus, Vir chief executive officer George Scangos told CNBC’s “Power Lunch” on Wednesday.
Scangos’ comments came after the two companies announced contracts to sell $ 1 billion of their antibody, sotrovimab, to the US government. The Food and Drug Administration granted sotrovimab emergency use authorization in May to treat up to moderate Covid infections in adults and children.

The antibody is administered intravenously, developed to target the peak Covid protein and prevent it from attaching and entering human cells, according to the FDA.

“It is certainly an effective antibody against Covid, but also against SARS, also against many other coronaviruses,” said Scangos. “So not only, I think, do we have an antibody that is resistant to all received variants of Covid, but can potentially help in future coronavirus pandemics as well. “

Although Scangos said the highly transmissible delta variant “is going to be with us for a while,” he added that sotrovimab could likely protect against newer variants that emerge in the future. Future mutations could even be variants of the delta itself, Scangos said, similar to the delta plus sub-variant that UK authorities have started monitoring in an increasing number of cases this fall.
Delta plus has two mutations in the spike protein that Covid uses to enter the body, but the subtype hasn’t evolved enough beyond delta to be considered its own variant.

Vir and GSK have received orders for 750,000 doses of their antibody therapy around the world, Scangos said. The companies will deliver the entire $ 1 billion order to the federal government by December 17, giving the United States the ability to purchase more doses until next March, according to a press release from Vir.

“It is important to note that this Covid can pass between humans and animals,” Scangos said. “And so as long as it has animal reservoirs and the virus can enter animal populations, mutate, generate new variants and come back to humans, we won’t be completely out of the woods. “

LEAVE A REPLY

Please enter your comment!
Please enter your name here